• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20545 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Andalusian Health Technology Assessment Area (AETSA) Electro-hipertermia modulada en pacientes con cáncer de páncreas, cáncer colorrectal avanzado y gliomas malignos
2022     Ontario Health First trimester screening for risk of preeclampsia using a multiple marker algorithm
2022     Center for Evidence-based Practice (CEP) Patient bias against healthcare providers
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: needs of children at-risk or in situation of neglect and those of their family]
2022     Health Information and Quality Authority (HIQA) High level review of configuration and reform of public health systems in selected countries
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of lung cancer in the Québec context]
2022     Austrian Institute for Health Technology Assessment (AIHTA) ATMPs and gene therapies in development. Horizon scanning – update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022     NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022     NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: relevance of the prerequisite of the use of an immunosuppressant drug for the coverage of biologic agents (gastroenterology and dermatology)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2022     Center for Evidence-based Practice (CEP) Clinical utility of inpatient fall risk assessment
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Center for Evidence-based Practice (CEP) Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022     Center for Evidence-based Practice (CEP) Testosterone reference ranges for gender diverse individuals
2022     Center for Evidence-based Practice (CEP) Breast cancer risk assessment tools
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022     Norwegian Institute of Public Health (NIPH) Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022     Norwegian Institute of Public Health (NIPH) [Operating room ventilation: a health technology assessment]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022     Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: classification of thickened liquids for dysphagia]
2022     Health Information and Quality Authority (HIQA) HTA of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2022     NIHR Health Technology Assessment programme Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: primary care and service quality indicators for supporting continuous quality improvement in Québec’s family medicine groups]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of medical care and services in long-term care facilities]
2022     NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Center for Evidence-based Practice (CEP) Restrictive red blood cell (RBC) transfusion thresholds: update
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: biologic dose escalation - gastroenterology, rheumatology and dermatology]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Image-guided spinal fusion technology]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022     NIHR Health Technology Assessment programme Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022     NIHR Health Technology Assessment programme Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
2022     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022     Scottish Health Technologies Group (SHTG) Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022     NIHR Health Technology Assessment programme Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022     NIHR Health Technology Assessment programme Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022     NIHR Health Technology Assessment programme Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022     Center for Evidence-based Practice (CEP) Workplace violence in healthcare settings
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: integration of real-world data and evidence into assessments to support decision-making in the pharmaceutical sector]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Intraocular lens implantation for infants with aphakia: a systematic review of clinical effectiveness and cost-effectiveness
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2022     NIHR Health Technology Assessment programme Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022     Norwegian Institute of Public Health (NIPH) Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022     Swiss Federal Office of Public Health (FOPH) Thyroid function tests for the diagnosis of suspected primary or secondary thyroid dysfunction
2022     Swiss Federal Office of Public Health (FOPH) Medicines for dementia due to Alzheimer's disease and Parkinson's disease
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post COVID-19 – effective treatment and rehabilitation]
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine as a treatment for subclinical hypothyroidism
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment of hyperemesis (severe nausea during pregnancy)]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Return to work – persons with long-term sickleave or welfare recipients
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment of women with diastasis recti]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Wheelchairs and wheelchair accessories]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposure and upper extremity pain]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bronchial thermoplasty in severe asthma]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022     Health Technology Wales (HTW) Virtual reality interventions for the management of pain associated with medical procedures
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients with moderate-severe malnutrition undergoing active treatment]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022     NIHR Health Technology Assessment programme Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022     NIHR Health Technology Assessment programme RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022     NIHR Health Technology Assessment programme E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022     NIHR Health Technology Assessment programme Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC PC)
2022     NIHR Health Technology Assessment programme The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022     NIHR Health Technology Assessment programme Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)